Review Article

Effectiveness and Safety of Electroacupuncture for Depression: A Systematic Review and Meta-Analysis

Zhuo Zhou, Guixing Xu , Liuyang Huang , Hao Tian , Fengyuan Huang , Yilin Liu , Mingsheng Sun , and Fanrong Liang

The Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China

Correspondence should be addressed to Fanrong Liang; acuresearch@126.com

Received 24 January 2022; Revised 23 May 2022; Accepted 3 June 2022; Published 18 August 2022

Academic Editor: George B. Lenon

Copyright © 2022 Zhuo Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. The purpose of this systematic review and meta-analysis was to comprehensively evaluate the efficacy and safety of electroacupuncture as an effective adjunctive therapy for patients with depression. Methods. Randomized controlled trials (RCTs) about the treatment of depression by electroacupuncture therapy from inception to September 2021 were searched and collected in eight databases. HAMD, SDS, and Adverse Reactions were used as outcome indicators. The quality of relevant articles was evaluated using the Cochrane Collaboration's risk of bias tool. The quality of evidence for each outcome was assessed through the Grading of Recommendations Assessment and the Development and Evaluation approach. Stata 15.0 software was used for data analysis. Results. A total of 16 depression-related RCTs were included in this meta-analysis. For the main outcome, electroacupuncture significantly reduced HAMD scores (I²:0.0%, SMD: -2.28% (95% CI-3.16 to -1.39)), and the quality of evidence was moderate. The improvement effect of electroacupuncture plus antidepressants was better than that of western drugs in patients with depression (I²:26.2%, SMD: -1.18% (95% CI-1.42 to -0.94)), and the quality of evidence was moderate. Electroacupuncture significantly reduced HAMD scores without significant heterogeneity (I^2 :0.0%, SMD: -3.76% (95%CI-5.78-1.73)). Studies with very low quality of evidence found that electroacupuncture was as effective as antidepressants in reducing SDS scores (I²:36.4%, WMD: -1.15% (95%CI-2.93-0.63)), and electroacupuncture was found to be more effective than sham electroacupuncture stimulation as well. Moderate quality evidence showed no statistical difference between electroacupuncture plus antidepressants/ electroacupuncture and antidepressants (12:0%, RR:1.05% (95%CI 0.73 to 1.53)). Conclusions. Our meta-analysis shows that electroacupuncture reduces HAMD scores. It is suggested to use electroacupuncture plus antidepressants to improve the curative effect and effectively reduce drug side effects.

1. Introduction

Depression is a common emotional disorder syndrome, mainly characterized by significant and persistent low spirits. Loss of interest, attention difficulties, feelings of guilt, loss of appetite, even suicidal thoughts, and other cognitive, behavioral, and social dysfunction are the main clinical manifestations of depression [1]. A persistent state of depression can cause serious harm to individuals and society. According to the World Health Organization, more than 300 million people are living with depression all around the world. A study showed that major depression is the most common mood disorder in China, with a lifetime prevalence of 3.4% and a 12-month prevalence of 2.1% [2]. At the same time, a meta-analysis has shown that depression treatment brings tremendous socioeconomic pressure [3], and depression is also ranked as the single largest contributor to nonfatal health loss [4].

The treatment of depression mainly includes psychotherapy, complementary and alternative medicine (CAM), exercise, and pharmacotherapy. However, due to the accelerated pace of modern life, drugs are often used as the treatment of choice. The second-generation antidepressants (SGAs) (selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and selective serotonin norepinephrine reuptake inhibitors) are the main drugs used to alleviate depression in clinical practice [5]. But studies [6] have shown that the drug has serious adverse reactions, even neuroleptic malignant syndrome (NMS), and a lack of safety for pregnant women and the elderly [7]. Therefore, it is urgent to find an effective and reliable alternative therapy to treat depression.

Acupuncture, as an intervention of traditional Chinese medicine, is widely used to treat neuropsychiatric diseases [8]. Studies have shown that acupuncture can regulate the limbic-paralimbic-neocortical network (LPNN), thus helping to improve the life and sleep quality of patients with depression [9]. Also, it has been recommended as a complementary alternative therapy in the United States [10]. Electroacupuncture (EA), a part of traditional acupuncture, is a combination of acupuncture and electrical stimulation that objectively controls the amount of stimulation. Through research, Sun et al. [11] proved that electroacupuncture is as effective as anti-depressants in the treatment of depression. Although some studies have provided partial evidence for EA in the treatment of depression [12], there is still a lack of high-quality RCTs to confirm the effectiveness and safety of EA for depression on the whole. Therefore, we included clinical studies related to EA treatment of depression with a Jadad score greater than or equal to 4. The primary outcome was the HAMD scale, and the secondary outcome was the SDS scale. At the same time, the safety of EA therapy in patients with depression is evaluated to report a more advanced objective validation of available data.

2. Materials and Methods

2.1. Study Registration. The SRs-MAs research was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. It was registered at INPLASY's International Prospective Register of Systematic Reviews (INPLASY202210068).

2.2. Eligibility Criteria

2.2.1. Types of Study. This study included all RCTs that have published Chinese or English articles about electroacupuncture for depression. At the same time, nonrandomized controlled trials, quasi-randomized controlled trials, conference papers, retrospective studies, medical record reports, protocols, reviews, article abstracts, and metaanalyses were excluded.

2.2.2. Types of Participants. All patients included in this study were diagnosed with depression according to [10] (ICD-10), the Diagnostic and Statistical Manual [1] (DSM-V, May 2013), or the Criteria for Classification and Diagnosis of Mental Diseases approved by the Chinese Psychiatric Science Committee [13].

2.2.3. Criteria for Intervention. Studies of EA for depression were included. Whether EA was used alone as an intervention or in combination with other treatments (western medicine,

moxibustion, transcranial electrical stimulation, and so on) can be included.

2.2.4. Criteria for Comparison. The control group was either treated with traditional western medicine, placebo, sham acupuncture, EA, or waited for treatment (with no intervention during the study). Psychological therapies (behavioral therapy, cognitive behavioral therapy, psychological counseling, etc.) were excluded from the intervention of the control group because of their strong subjectivity.

2.2.5. Outcome. The Hamilton Depression Rating Scale for Depression (HAMD17/24) was considered as the primary outcome index of this study, while the self-rating depression scale (SDS) and adverse reactions that occurred during treatment were regarded as secondary outcome indexes. Adverse reactions and follow-up data were statistically analyzed to evaluate the safety of electroacupuncture for depression treatment.

2.3. Search Strategy. The following eight databases will be searched from inception to 10th September 2021: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), VIP Database, and WanFang Database. We followed key search terms and their potential combinations on PubMed: (1) clinical condition: depression, depressive disorders, depress, Journal Pre-proof "affective disorder, affective symptoms; (2) acupuncture terms: electroacupuncture, Electric acupuncture, EA, Electroacupuncture therapy, Electroacupuncture therapy, Electric acupuncture therapy; (3) study type: randomized controlled trial. We used "and" and "or" to connect the search terms. Search strategies are shown in Table 1.

2.4. Study Selection and Data Extraction. In this study, two reviewers (ZZ and XGX) searched the above databases in no particular language. After preliminary screening according to the titles and abstracts of the articles, duplicate references were deleted using Endnote. After fulltext reading, the remaining articles that could be included in this study were identified, and then information extraction was carried out. Two reviewers (ZZ and XGX) independently extracted data from the included trials, mainly including the data extraction table name, author, name of the magazine, published literature, diagnostic criteria, number, time of intervention, treatment, and outcome indicators, adverse events, and other aspects. These data were recorded by Office 2019. If the information is incomplete, we will contact the authors by phone or e-mail to acquire more information. When disagreements arise in the research, they are resolved through discussion or consultation with a third reviewer (LFR) until consensus is reached.

TABLE 1: Search strategy for Cochrane library database.

#1	Randomized controlled trial [All text]
#2	Controlled clinical trial [All text]
#3	Randomized [All text]
#4	Randomized [All text]
#5	Placebo [All text]
#6	Randomly [All text]
#7	Trial [All text]
#8	Groups [All text]
#9	Or/#1-#8
#10	Depression [Title/Abstract/Keyword]
#11	Depressive disorder [Title/Abstract/Keyword]
#12	#10 or #11
#13	Electroacupuncture [Title/Abstract/Keyword]
#14	Electric acupuncture [Title/Abstract/Keyword]
#15	EA [Title/Abstract/Keyword]
#16	Electroacupuncture therapy [Title/Abstract/Keyword]
#17	Electroacupuncture therapy [Title/Abstract/Keyword]
#18	Electric acupuncture therapy [Title/Abstract/Keyword]
#19	Or/#13-#19cWarm needle [Title/Abstract/Keyword]
#20	#9 and #12 and #19

This search strategy was modified to be suitable for other electronic databases.

2.5. Risk of Bias and Quality Assessment. Two reviewers (HLY and TH) independently assessed the risk of bias in the final included studies using the risk of bias assessment tool developed by the Cochrane Collaboration [14]. This standard included six items of selection bias, performance bias, detection bias, attrition bias, reporting bias, and other biases, and each standard was divided into "low" bias risk, "high" bias risk, and "unclear" bias risk. Two independent researchers (HFY and LYL) evaluated the legal quality by the Jadad scale [15]. Any ambiguity in the evaluation process was resolved by LFR. Only high-quality studies with Jadad scores greater than or equal to 4 were included in this study.

After the Cochrane Collaboration's Bias Risk Tool and Jadad score were completed, we graded the quality of evidence for each study. The Grading of Recommendations Assessment, Development, and Evaluations (GRADE) system was used to evaluate the evidence quality of the outcomes [16]. The evaluation of the level of evidence included risk of bias, inconsistency, indirectness, imprecision, and publication bias, and it was divided into four grades: high, moderate, low, and very low.

2.6. Statistical Analysis. Statistical analyses were performed using STATA 15.0 software in our study. After the inclusion information was sorted out, groups were divided according to the type of intervention and control method. If the RCTs set up three matched control groups, they were split and compared in pairs. For the main outcome indicators—HAMD-17/24, we converted the corresponding scores of HAMD-17 into the scores of phase HAMD-24. Meanwhile, we unified the units of each result of different trials according to the international system of units and then imported clinical data into STATA 15.0.

Random-effects models were used to analyze dichotomous and continuous data for risk ratio (RR), standard mean difference (SMD), and 95% confidence intervals (95% CI). Q statistics were used to investigate the heterogeneity between studies, P values <0.10 were considered an indicator of significant heterogeneity. When the heterogeneity test $I^2 < 75\%$, the random effects model was used for data synthesis. If there was considerable heterogeneity in the experiment ($I^2 > 75\%$ or P < 0.10), each trial was removed from the population analysis. At the same time, sensitivity analysis was performed to identify studies that significantly affected the population effect. When we included enough trials, the funnel plot was visually examined, and Egger or Begg tests were used to quantitatively evaluate publication bias. The subgroup analysis or meta-regression was not conducted due to a few heterogeneities.

3. Results

3.1. Results on Literature Search and Selection. We obtained 4884 records from the eight databases through the retrieval strategy in advance and eliminated 2728 duplicate records before preliminary screening. After reading the titles and abstracts, 114 eligible studies were left. Jadad scores were performed on the literature, and 98 trials with Jadad scores of less than 4 points were excluded. Table 2 shows the Jadad score of the included trial (Jadad ≥4). A total of 16 RCTs met the inclusion criteria. Study selection flow chart is shown in Figure 1.

3.2. Characteristics of Included Reviews. Our study included 16 [11, 17–31] RCTs of electroacupuncture/electroacupuncture plus antidepressant drugs versus sham-electroacupuncture/antidepressants. There are two control groups for Sun H et al. [11, 20, 25], 8 trials [11, 19, 21–24, 26, 31] used electroacupuncture alone as an intervention, and 8 studies [17, 18, 20, 27–31] used acupuncture plus antidepressants. A total of 1428 participants were enrolled in the trial with a sample size range of 316~40 and a mean age of 40 (range 30~48). At the baseline, the mean HAMD-24 score was 37.04 (range23.8–47.36). The main characteristics and the specific interventions of each identified study are presented in Table 3.

3.3. Risk of Bias Assessment. All of the 16 studies [11, 17–31] mentioned the random sequence generation methods, including computer program random sequencing, random number tables, or random number generators, and were assessed as having a low risk of bias. Among the allocation concealment methods, 8 studies [11, 17, 23, 24, 26–28, 31] were carried out using the sealed envelope method, the random list method, the random allocation method, or the coin method to determine single and even grouping, with a low risk of bias, while the other 8 trials [18–22, 25, 29, 30] were unclear because they did not mention or describe any method of allocation concealment. Due to the active manipulation of EA, most clinical studies could not be completely blinded. About the blinding of participants and

Study ID	Random sequence generation	Allocation concealment	Blinding	Withdrawals and lost visits	Total
Ma_2011	2	2	2	1	7
wang_2014	2	2	2	1	7
Qu_2015	2	2	1	1	6
Wang_2010	2	2	1	1	6
Zhao_2019	2	2	1	1	6
Luo_2003	1	1	2	1	5
Li_2011	2	2	0	1	5
Wang_2014	2	2	0	1	5
Duan_2011	2	1	1	1	5
Qu_2013	2	1	1	1	5
Sun_2013	2	2	0	1	5
Zhang_2012	2	1	2	0	5
Lin_2012	2	1	0	1	4
Lin_2012	2	1	0	1	4
Chen_2013	2	1	0	1	4
Wang_2013	2	1	0	1	4

TABLE 2: Jadad score in included studies.




FIGURE 1: Flowchart of study selection.

investigators, 7 studies [11, 22, 23, 26, 27, 29, 30] were highrisk studies, 5 RCTs [17, 20, 21, 28, 31] were unclear, and only 4 [18, 24–26] of blindness were evaluated as low risk. 4 RCTs [18, 24–26] reported in detail the outcome assessment of blindness and were rated as low risk. In terms of data integrity, all 16 studies have been described in detail, so we believe that all studies have a low risk of bias. In the 9 studies [17, 18, 20, 21, 24–28, 30, 31] we included all expected outcomes reported, including adverse events, and were assessed as low risk of bias. The remaining studies either did not document the protocol or did not mention adverse events, so the risks were not clear. Other sources of bias, 2 [11, 27] high-risk, 4 [17, 18, 20, 31] low-risk, others unclear. Table 4 presents the risk of bias in each trial.

Therapeutics Times Therapeutics	. E																							
			Times Th	Therapeutics	Times	Course Experi	Experimental Control	itrol Control		Experimental Co	Control Cor	Control Exper	Experimental C	Control	Control	Experimental	Control	Control	Experimental	Control	Control	Experimental	Control	Contro
EA + D 18	8	SSRIs 1	NA			Weeks It	50 I [±]				57 N	IA 41.18		76 ± 12.85	NA	10.77 ± 15.32	9.52 ± 13.85	NA	45.36 ± 5.53	44.32 ± 5.42	NA	NA	NA	NA
EA 36	6 FL		NA			5Weeks 3	6 3		V	3	13 N	IA 3.		35 ± 8	NA	7.2 ± 2.4	7.2 ± 2.4	NA	23.8 ± 4	25.1 ± 3.7	NA	NA	NA	NA
SA + D 18	8 Pa		NA			SWeeks 5	8 4	8 Z	Y V	13	N 8			$A \pm 10.8$	NA	19.8 ± 22.4	20.8 ± 26.1	NA	45.19 ± 6.99	42.12 ± 4.03	NA	22	19	NA
EA 30	0		Times 1			Weeks 2	0 1		5	8	3	3 43.10		¥6±10.70 40	0.72 ± 12.80	24.84 ± 8.66	38.4 ± 17.6	28.2 ± 14.9	23.80 ± 2.93	22.81 ± 3.25	23.32 ± 3.49	NA	NA	NA
5A + D 9	9 Flu		Times			Weeks 3	8		. V	1	1			$.26 \pm 9.8$	NA	7.96 ± 8.0	7.36 ± 7.1	NA	43.2 ± 5.11	41.76 ± 4.48	NA	14	1	NA
EA 28	8 Pa		NA			1Weeks 3	0 3		Y	0.	II N			45 ± 4	NA	48 ± 2.42	50.4 ± 2.77	NA	28.17 ± 2.17	28.10 ± 1.18	NA	NA	NA	NA
EA 72	'2 Pa		NA			4 Weeks 3	0 3		V	7	8			$.1 \pm 10.6$	NA	9.45 ± 9.24	15.75 ± 21.3	NA	NA	NA	NA	2	4	ΝA
			NA			Weeks 2	8 3		Y	. 8	20 N	4		30 ± 14.71	NA	3.5 ± 2.69	3.89 ± 3.56	NA	25.57 ± 4.83	26.29 ± 6.01	NA	4	9	NA
			0Times			2 Weeks 3	2 3		V	6	11 N			$.8 \pm 2.16$	NA	NA	NA	NA	27.56 ± 1.08	26.69 ± 0.67	NA	NA	ΝA	ΝN
			NA			Weeks 6	4 6			.3	31 N	ŝ		58 ± 10.62	NA	10.47 ± 23.25	12.15 ± 1691	NA	36.75 ± 3.99	38.99 ± 4.8	NA	1	19	3
			Weeks			Weeks 3	1 3.				14 N	,		22 ± 11.07	NA	17.58 ± 20.45	19.06 ± 23.78	NA	46.42 ± 6.82	42.64 ± 5.96	NA	2	4	NA
EA 30	0		NA			Weeks 3	0 3		Y	12	10 N	4		37±12.20	NA	6.37 ± 2.41	6.47 ± 3.33	NA	34.07 ± 4.27	35.07 ± 3.52	NA	0	4	NA
EA 30	0 Fh		NA	æ3		Weeks 3	1 3.							34±13	32 ± 12	NA	NA	NA	22.42 ± 2.93	22.16 ± 2.16	22.84 ± 3.47	NA	NA	NA
			NA			Weeks 2	3 1		V	3	9 V		_	48 ± 9	NA	NA	NA	NA	47.36 ± 5.28	45.98 ± 5.53	NA	NA	NA	ΝA
			NA			Weeks 3	4 3				14 N	ŝ		31 ± 11.49	NA	NA	NA	NA	47.56 ± 7.35	42.52 ± 5.89	NA	NA	NA	NA
			NA	NA	Ĩ	Weeks 4	6 5				15 N			38 ± 10	NA	4.72 ± 2.4	4.48 ± 2.7	NA	45.26 ± 7.42	42.23 ± 5.82	NA	NA	NA	NA
			VVI	VN1		AV CCAS	5							NT I OC	VN1	4'77 I 7/'%	/'7 I 01-'1-	NN N	74.1/ I 07.04	70'C I C7'74	INV	VN1		VV.
		18 18 19 10 10 10 10 10 10 10 10 10 10 10 10 10	 ISSRIS FISS Paroserine Par	18 18 19 10 10 10 10 10 10 10 10 10 10 10 10 10	 B. SSRIS. NA NA B. Bluscénie NA NA B. Pluscénie NA NA B. Paroschie NA NA P. D. D.	16 SSRM NA NA NA 18 Fluoratine NA NA NA 18 Paronetine NA NA NA 9 Paronetine NA NA NA 9 Paronetine NA NA NA 72 Paronetine NA NA NA 173 Paronetine NA NA NA 120 Paronetine NA NA NA 121 Paronetine NA NA NA 120 SIA 120Times NA NA 120 SIA 120Times NA NA 120 SIA NA NA NA 131 Paronetine NA NA NA 132 Paronetine NA NA NA 138 Paronetine NA NA NA 148 Paronetine NA NA NA <t< td=""><td> B. SSRIS. NA NA B. Bluscénie NA NA B. Pluscénie NA NA B. Paroschie NA NA P. D. D.</td><td>18 SRMs NA NA 60 160 1 18 Prometrine NA NA NA 60 160 1 18 Prometrine NA NA NA 60 86 19 Prometrine NA NA NA 60 86 19 Fluencettine NA NA NA 60 86 27 Parometrine NA NA NA 86 9 27 Parometrine NA NA NA 86 9 28 Parometrine NA NA NA 86 9 29 Parometrine NA NA NA 80 9 210 SIM NA NA NA 80 9 210 SIM NA NA NA 80 9 210 SIM NA NA NA 80 9 210 SIM</td><td>18 SSRIs NA NA NA NA NA NA SNE 160 156 18 Punertine NA NA NA NA 600 156 18 Punertine NA NA NA 600 600 156 30 Planetine NA NA NA 600 600 156 31 Punertine NA NA NA 600 600 156 32 Planetine NA NA NA 600 9 30 33 Planetine NA NA NA 600 30 30 34 Panostine NA NA NA ANeels 30 30 35 Panostine NA NA NA NA 600 53 32 36 Provertine NA NA NA NA 600 53 32 30 SRIs NA<</td><td>18 SR38, NA NA</td><td>36 SNMs NA NA Weeks 155 NA 22 36 Provertine NA NA NA NA NA 24 23 30 Exometine NA NA NA NA NA 24 24 30 Ex 37truss Huserine NA NA 66 15 NA 33 30 EX 37truss Huserine NA NA 66 33 34 31 31 Provertire NA NA NA 9 30 NA 10 7 Provertire NA NA NA 49 33 34 11 31 Provertire NA NA 40 66 33 34 11 32 Provertire NA NA 40 66 33 34 11 31 Provertire NA NA 66 33 34</td><td>18 SN34 NA NA NA NA NA NA SN4 SN4 S2 S2 S2 S3 S3</td><td></td><td>16 SISIA NA NA</td><td>16 StRA, NA NA</td><td>16 StRA, NA NA</td><td></td><td>18 SRIs NA N</td><td></td><td></td><td>16 SSMA NA Stata Stata NA Stata Stata NA Stata NA Stata NA Stata Stata NA Stata Stata NA Stata</td></t<> <td>16 RM NA State State NA State NA State State NA State State</td> <td></td> <td></td>	 B. SSRIS. NA NA B. Bluscénie NA NA B. Pluscénie NA NA B. Paroschie NA NA P. D. D.	18 SRMs NA NA 60 160 1 18 Prometrine NA NA NA 60 160 1 18 Prometrine NA NA NA 60 86 19 Prometrine NA NA NA 60 86 19 Fluencettine NA NA NA 60 86 27 Parometrine NA NA NA 86 9 27 Parometrine NA NA NA 86 9 28 Parometrine NA NA NA 86 9 29 Parometrine NA NA NA 80 9 210 SIM NA NA NA 80 9 210 SIM NA NA NA 80 9 210 SIM NA NA NA 80 9 210 SIM	18 SSRIs NA NA NA NA NA NA SNE 160 156 18 Punertine NA NA NA NA 600 156 18 Punertine NA NA NA 600 600 156 30 Planetine NA NA NA 600 600 156 31 Punertine NA NA NA 600 600 156 32 Planetine NA NA NA 600 9 30 33 Planetine NA NA NA 600 30 30 34 Panostine NA NA NA ANeels 30 30 35 Panostine NA NA NA NA 600 53 32 36 Provertine NA NA NA NA 600 53 32 30 SRIs NA<	18 SR38, NA NA	36 SNMs NA NA Weeks 155 NA 22 36 Provertine NA NA NA NA NA 24 23 30 Exometine NA NA NA NA NA 24 24 30 Ex 37truss Huserine NA NA 66 15 NA 33 30 EX 37truss Huserine NA NA 66 33 34 31 31 Provertire NA NA NA 9 30 NA 10 7 Provertire NA NA NA 49 33 34 11 31 Provertire NA NA 40 66 33 34 11 32 Provertire NA NA 40 66 33 34 11 31 Provertire NA NA 66 33 34	18 SN34 NA NA NA NA NA NA SN4 SN4 S2 S2 S2 S3 S3		16 SISIA NA NA	16 StRA, NA NA	16 StRA, NA NA		18 SRIs NA N			16 SSMA NA Stata Stata NA Stata Stata NA Stata NA Stata NA Stata Stata NA Stata Stata NA Stata	16 RM NA State State NA State NA State State NA State State		

÷
stud
fied
lenti
:9
each
of
acteristics
char
The
3:
TABLE 3

Study ID	Random sequence generation	Allocation concealment	Blinding of participants and investigators	Blinding of outcome assessment	Incomplete data	Selective reporting	Other bias
Zhao_2019	Low	Low	Unclear	Unclear	Low	Low	Low
Duan_2011	Low	Unclear	Unclear	Unclear	Low	Low	Unclear
Qu_2013	Low	Unclear	Unclear	Unclear	Low	Low	Low
Sun_2013	Low	Low	High	High	Low	Unclear	High
Zhang_2012	Low	Unclear	Low	Low	Low	Low	Low
Chen_2013	Low	Unclear	High	High	Low	Unclear	Unclear
Wang_2013	Low	Unclear	High	High	Low	Unclear	Unclear
Ma_2011	Low	Low	Low	Low	Low	Low	Unclear
Wang_2014	Low	Low	Low	Low	Low	Low	Unclear
Qu_2015	Low	Low	Unclear	Unclear	Low	Low	Low
Wang_2010	Low	Low	Unclear	Unclear	Low	Unclear	Unclear
Li_2011	Low	Low	High	Unclear	Low	Unclear	Unclear
Luo_2003	Low	Unclear	Low	Low	Low	Low	Unclear
Wang_2014	Low	Low	High	High	Low	Unclear	High
Lin_2012	Low	Unclear	High	High	Low	Low	Unclear
Lin_2012	Low	Unclear	High	High	Low	Unclear	Unclear

TABLE 4: Risk of bias in included studies.




FIGURE 2: Forest diagram of HAMD-24 for electroacupuncture vs. antidepressants.

3.4. Effectiveness of EA

3.4.1. HAMD-24. A total of 15 RCTs (except [19]) investigated the effect of electroacupuncture on HAMD scores in our meta. Meta-analysis of 7 RCTs (Sun_2013 [11] had two control groups) involving 8 trials (506 participants) revealed significant differences in HAMD score reduction between electroacupuncture and antidepressants (SMD: -1.84 (95% CI -3.05 to -0.64), I^2 :48.9%, Figure 2), and no significant publication bias (Figure 3). Heterogeneity disappeared after Li_2011 [23]was removed (I2:0.0%, SMD: -2.28% (95% CI-3.16 to -1.39), with moderate quality evidence (Figure 4 and Table 5). Pooled 8 studies found that electroacupuncture plus antidepressants was more effective in improving the patients' depression (SMD: -6.83% (95% CI -8.39 to -5.27), I2:66.4%, Figure 5), compared with antidepressants. Heterogeneity was significantly reduced after Zhao_2019 [17] was removed and evidence quality was moderate (I2:26.2%,




FIGURE 3: Egger test of HAMD for electroacupuncture vs. antidepressants.




FIGURE 4: Forest diagram of HAMD for electroacupuncture vs antidepressants removed Li_2011.


SMD: -1.18% (95% CI-1.42 to -0.94), Figure 6, Figure 7, and Table 5). There were only 2 studies [25, 26]that compared electroacupuncture with sham electroacupuncture, and the quality of evidence was moderate (I2: 0.0%, SMD: -3.76% (95% CI-5.78 to -1.73)).

In follow-up, a meta-analysis of 6 studies with moderate quality evidence showed that electroacupuncture plus antidepressants therapy was more effective than antidepressants therapy alone (I2: 35.7%, WMD: -6.19% (95% CI-8.01 to -4.38), Figure 8). 3.4.2. SDS. SDS scores were mentioned in the results of 9 trials. Pooled 7 studies found that electroacupuncture alone or plus antidepressants and antidepressants had no significant differences in reducing SDS (I2:62.6%, WMD: -1.92% (95% CI -4.06 to 0.21), see Figure 9). Although sensitivity analysis reduced heterogeneity (I2:36.4%, WMD: -1.15% (95% CI -2.93 to 0.63), Figure 10, and Figure 11), the quality of evidence was very low (Table 5). The remaining two studies [8, 25] suggested that electroacupuncture was more effective than sham electroacupuncture (WMD: -5.39 (95%)


		T	TABLE 5: GRADE quality assessment of evidence.	quality assessi	ment of evide	nce.				
Intervention	Outcome indicators	Risk of bias	Inconsistency Indirectness Imprecision	Indirectness	Imprecision	Publication bias	Large effect	Dose- response	All plausible confounding	Quality of evidence
Electroacupuncture versus sham-	HAMD-24 SDS	-1^{a} 0	0	0	$0 - 1^{c}$	0	0	0	0 0	Moderate Moderate
electi vacupuliture	Side effect	0	0	0	0	0	0	0	0	High
	HAMD-24	-1^{a}	0	0	0	0	0	0	0	Moderate
Electroactuputterne versus	SDS	-1^{a}	-1 ^b	0	-1 ^c	0	0	0	0	Very low
annuchressanus	Side effect	0	-1^{b}	0	0	0	0	0	0	Moderate
	HAMD-24	-1^{a}	-1^{b}	0	0	0	0	0	0	Low
Di octavo cumunactura aluc antidomenacto	SDS	-1^{a}	-1^{b}	0	0	0	0	0	0	Low
versus antidepressants	HAMD-24 follow-up	-1 ^a	0	0	0	0	0	0	0	Moderate
	Side effect	0	-1^{b}	0	0	0	0	0	0	Moderate
<i>Note.</i> GRADE, the grading of recommendations assessment, development and evaluation; HAMD-24, 24-item hamilton rating scale for depression; SDS, zung self-rating depression scale; ^a included studies have risk of bias; ^b heterogeneity of meta-analysis; ^c small sample size; ^d potential publication bias.	assessment, develo all sample size; ^d	pment and ootential pu	evaluation; HAMD ublication bias.	-24, 24-item ha	milton rating s	cale for depressio	n; SDS, zung	g self-rating depr	ession scale; ^a include	d studies have

of evide	
assessment	
quality	
GRADE	
5.	
TABLE	


8



-14.8



0



Meta-analysis estimates, given named study is omitted

14.8

FIGURE 6: Sensitivity analyses of electroacupuncture plus antidepressants vs. antidepressants for HAMD-24.




FIGURE 7: Forest diagram of HAMD for electroacupuncture plus anti-depressants vs. antidepressants removed Zhao_2019.




FIGURE 8: Forest diagram of HAMD for electroacupuncture vs. antidepressants in follow-up.

CI: -8.82 to -1.97), I2 = 0%), and the quality of evidence was high.

In follow-up, electroacupuncture may be more effective than antidepressants (I²: 89.1%, WMD: -6.19 (95% CI -10.87 to -4.67)) with moderate quality of evidence.

3.5. *Safety of EA*. Pooled 7 studies showed no statistical difference between electroacupuncture plus antidepressants/ electroacupuncture and antidepressants, with moderate

quality evidence (I^2 : 55.9%, RR: 0.69% (95% CI 0.73 to 1.38), see Figure 12). After sensitivity analysis and the elimination of Qu_2015, heterogeneity disappeared, but there was still no significant difference. (I^2 : 0%, RR: 1.05% (95% CI 0.73 to 1.53), see Figure 13 and Figure 14)

4. Discussion

Our meta-analysis included 16 high-quality RCTs with EA as the primary intervention, involving 1428 patients with Evidence-Based Complementary and Alternative Medicine




FIGURE 9: Forest diagram of SDS for electroacupuncture vs. antidepressants.

Meta-analysis estimates, given named study is omitted




FIGURE 10: Sensitivity analyses of electroacupuncture vs. antidepressants for SDS.

depression, and we found that EA is promising as an alternative treatment for depression. The significant effect of EA on depressed patients was not a placebo effect, and EA/ EA plus antidepressants therapy can significantly reduce the HAMD scores and SDS scores compared with drugs. In addition, as an adjunctive therapy, EA can not only




FIGURE 11: Forest diagram of SDS for electroacupuncture vs. antidepressants removed Qu_2013.




FIGURE 12: Forest diagram of adverse events for electroacupuncture vs. antidepressants.

significantly improve the clinical therapeutic effect but also effectively reduce the incidence of adverse drug reactions.

The pathogenesis of depression is mainly related to the insufficiency of neurotransmitters such as 5-hydroxytryptamine (5-HT) and noradrenalin (NE) in the brain. Besides, Gammaaminobutyric acid (GABA), brain-derived neurotrophic factor (BDNF), and dopamine (DA) also participate in the pathogenetic process of depression [32, 33]. There is growing evidence that EA has benefits in treating depression. Study [34] has suggested that EA can improve the synaptic plasticity of the prefrontal cortex by upregulating GluR1 and NR2B expression levels, thus




FIGURE 13: Sensitivity analyses of adverse events for electroacupuncture vs. antidepressants.




FIGURE 14: Forest diagram of adverse events for electroacupuncture vs. antidepressants.

contributing to antidepressant effects. Li et al. [35] found that EA may improve the depression behavior of rats by upregulating p11mRNA expression in the raphe nucleus and promoting 5-htr4 expression in the plasma membrane of glutamate neurons. Although similar meta-analyses have been conducted in the past to prove the effectiveness of acupuncture on depression [36–38], compared with Zhang et al. [36] and Wang et al. [37], we only included studies with a Jadad score \geq 4 to ensure the high quality of research results. At the same time, our study excluded the influence of

other treatment methods on the study and only compared the difference between EA therapy/drugs/sham EA therapy, and excluded the comforting effect of EA. More critically, in addition to focusing on the adverse effects of EA for depression, we also explored the follow-up period to definitively determine the long-term efficacy of EA for depression.

Due to the characteristics of EA operation, the deficiency of blindness is the biggest reason for the deviation. In addition, the included study section did not report in detail the calculation of its sample size. Differences in sample size and course of the disease, the selection of acupoints, and EA frequency of studies increase the heterogeneity, which all reduce the level of evidence. There are some other limitations. All the studies were conducted in China, where acupuncture has a high acceptance as a traditional form of treatment, which may be another source of bias. Besides, this study only regarded electroacupuncture as the only intervention of TCM and neglected to explore the combined use of other treatment methods for better efficacy.

Acupuncture is not the only treatment for depression, but our study demonstrates that EA can significantly improve symptoms of depression. It also reduces the side effects of medication as a safe treatment. However, depression is a chronic and relapsing disease associated with mood, and a large-sample size and long-term follow-up studies are still needed in future studies. It is necessary for us to explore the optimal treatment frequency and acupoint selection of EA therapy to understand its long-term effects for better clinical application. Thus, EA treatment of depression has greater clinical application space. We hope that more high-quality, large-sample studies will confirm our findings in the future.

5. Conclusions

In summary, despite the above limitations, the high-quality RCTs we included still suggested that electroacupuncture could reduce HAMD score, and we also suggested that electroacupuncture plus antidepressants should be used to enhance efficacy and effectively reduce drug side effects.

Data Availability

The data analyzed in this meta-analysis and systematic review are derived from published articles and can be retrieved from the previous eight databases.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

Acknowledgments

This study has been supported by the National Natural Science Foundation (Nos. 81590950, 81590951, and 82004486) and the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (No. ZYYCXTD-D-202003), China.

Supplementary Materials

Appendix 1: sensitivity analyses of electroacupuncture vs antidepressants for HAMD-24. Appendix 2: forest diagram of SDS for electroacupuncture vs sham-electroacupuncture. Appendix 3: forest diagram of SDS for electroacupuncture vs antidepressants in follow-up. (*Supplementary Materials*)

References

- D. E. Battle, "Diagnostic and statistical manual of mental disorders (DSM)," Coda, vol. 25, no. 2, pp. 191-192, 2013.
- [2] Y. Huang, Y. Wang, H. Wang et al., "Prevalence of mental disorders in China: a cross-sectional epidemiological study," *The Lancet Psychiatry*, vol. 6, no. 3, pp. 211–224, 2019.
- [3] H. König, H. H. König, and A. Konnopka, "The excess costs of depression: a systematic review and meta-analysis," *Epidemiology and Psychiatric Sciences*, vol. 29, 2020.
- [4] P. Alter, H. Watz, K. Kahnert et al., "Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling," *Respiratory Medicine*, vol. 137, pp. 14–22, 2018.
- [5] H. Sakurai, H. Uchida, M. Kato et al., "Pharmacological management of depression: Japanese expert consensus," *Journal of Affective Disorders*, vol. 266, pp. 626–632, 2020.
- [6] M. Belvederi Murri, A. Guaglianone, M. Bugliani et al., "Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis," *Drugs* in R & D, vol. 15, no. 1, pp. 45–62, 2015.
- [7] P. Damkier and P. Videbech, "The safety of second-generation antipsychotics during pregnancy: a clinically focused review," *CNS Drugs*, vol. 32, no. 4, pp. 351–366, 2018.
- [8] S. F. Xu, P. Yin, J. Y. Wu, and Y. Cao, "Survey of the application of behavioral assessment to experimental studies of acupuncture treatment for nervous and mental diseases," *Shanghai Journal of Acupuncture and Moxibustion*, vol. 33, no. 03, pp. 278–282, 2014.
- [9] P. Bosch, M. van den Noort, H. Staudte, and S. Lim, "Schizophrenia and depression: a systematic review of the effectiveness and the working mechanisms behind acupuncture," *Explore*, vol. 11, no. 4, pp. 281–291, 2015.
- [10] R. C. Kessler, J. Soukup, R. B. Davis et al., "The use of complementary and alternative therapies to treat anxiety and depression in the United States," *American Journal of Psychiatry*, vol. 158, no. 2, pp. 289–294, 2001.
- [11] H. Sun, H. Zhao, C. Ma et al., "Effects of electroacupuncture on depression and the production of glial cell line-derived neurotrophic factor compared with fluoxetine: a randomized controlled pilot study," *Journal of Alternative & Complementary Medicine*, vol. 19, no. 9, pp. 733–739, 2013.
- [12] Y. Cao, W. Cao, J. Yuan et al., "Efficacy and safety of acupuncture for postpartum depression: a systematic review," *Chinese Journal of Evidence-Based Medicine*, vol. 21, no. 08, pp. 922–928, 2021.
- [13] X. F. Zhang, Q. Qin, W. Y. Geng et al., "Electroacupuncture reduces hypothalamic and medullary expression of orexins and their receptors in a rat model of chronic obstructive pulmonary disease," *Acupuncture in Medicine*, vol. 36, no. 5, pp. 312–318, 2018.
- [14] J. P. T. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, Wiley, Hoboken, NJ, USA, 2011.
- [15] J. Ma, Y. Liu, L. P. Zhong, C. P. Zhang, and Z. Y. Zhang, "Comparison between Jadad scale and Cochrane"

collaboration's tool for assessing risk of bias on the quality and risk of bias evaluation in randomized controlled trials," *China Journal of Oral and Maxillofacial Surgery*, vol. 10, no. 05, pp. 417–422, 2012.

- [16] J. J. Meerpohl, G. Langer, M. Perleth, G. Gartlehner, A. Kaminski-Hartenthaler, and H. Schünemann, "[GRADE guidelines: 3. Rating the quality of evidence (confidence in the estimates of effect)]," *Journal Evidence for Education and Quality in Healthcare*, vol. 106, no. 6, pp. 449–456, 2012.
- [17] B. Zhao, Z. Li, Y. Wang et al., "Can acupuncture combined with SSRIs improve clinical symptoms and quality of life in patients with depression? Secondary outcomes of a pragmatic randomized controlled trial," *Complementary Therapies in Medicine*, vol. 45, pp. 295–302, 2019.
- [18] Z. J. Zhang, R. Ng, S. C. Man et al., "Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study," *PLoS One*, vol. 7, no. 1, Article ID e29651, 2012.
- [19] W. D. Wang, X. Y. Lu, S. M. Ng et al., "Effects of electroacupuncture on personality traits in depression: a randomized controlled study," *Chinese Journal of Integrative Medicine*, vol. 19, no. 10, pp. 777–782, 2013.
- [20] S. S. Qu, Y. Huang, Z. J. Zhang et al., "A 6-week randomized controlled trial with 4-week follow-up of acupuncture combined with paroxetine in patients with major depressive disorder," *Journal of Psychiatric Research*, vol. 47, no. 6, pp. 726–732, 2013.
- [21] D. M. Duan, Y. Tu, S. Jiao, and W. Qin, "The relevance between symptoms and magnetic resonance imaging analysis of the hippocampus of depressed patients given electro-acupuncture combined with Fluoxetine intervention-a randomized, controlled trial," *Chinese Journal of Integrative Medicine*, vol. 17, no. 3, pp. 190–199, 2011.
- [22] X.-l. Chen, K. Xu, R.-h. Luo, and M.-j. Lin, "Electroacupuncture in treating depression: a randomized controlled study," *Journal of Acupuncture and Tuina Science*, vol. 11, no. 1, pp. 42–45, 2013.
- [23] S. W. Li, Clinical Research on Depression of Liver-Depression and Spleen-Deficiency with Electro-Acupuncture Treament of Fixed-Frequency, Guangzhou University of Chinese Medicine, Guangzhou, China, 2011.
- [24] X. H. Ma, *The Clinical Study on Acupuncture Anti-depression*, Beijing university of TCM, Beijing, China, 2011.
- [25] H. C. Luo, U. Halbriech, and Y. T. Shen, "Comparative study of electroacupuncture and fluoxetine for treatment of depression," *Chinese Journal of Psychiatry*, vol. 60, no. 04, pp. 26–30 2014.
- [26] H. H. Wang, Electrical Stimulation of the Auricular Region in Mild to Moderate Depression:A Randomized Controlled Trial, Beijing university of TCM, Beijing, China, 2014.
- [27] S. H. Wang, Z. Y. Wang, and X. H. Ma, "Study on alleviating side effect of parotine and improving quality of life using acupunctuew in treatment of mild or moderate depression," *The Chinese Journal of Behavioral Medicine and Brain Science*, vol. 23, no. 03, pp. 211–214, 2014.
- [28] Z. Q. Wang, The Cllnical Research On the Combination of Electroacupuncture and Xeroxat (paroxetine HCI) in Treating Depression, Southern Medical University, Guangzhou, China, 2010.
- [29] Y. H. Lin and L. L. Wang, "Clinical comparative study of electro-acupuncture and manual acupuncture in treating depression," *Shanghai Journal of Acupuncture and Moxibustion*, vol. 31, no. 02, pp. 77–79, 2012.

- [30] W. R. Lin, Y. Huang, J. Q. Chen, and S. X. Wang, "Global improvement in agitated depression treated with the alliance therapy of acupuncture and seroxatand the observation of the quality of life," *Chinese Acupuncture & Moxibustion*, vol. 32, no. 12, pp. 1063–1069, 2012.
- [31] S. S. Qu, The Clinical and Rs-fMRI Study on Mild-To-Moderate Primary Depression Treated with Electro-Acupuncture at GV24 and GV29, Southern Medical University, Guangzhou, China, 2015.
- [32] X. Y. Chen, Y. F. Li, C. X. Xu, and F. H. Qiao, "Research progress on the mechanism of acupuncture on depression in central 5-HT system," *Chinese Archives of Traditional Chinese Medicine*, vol. 41, no. 13, pp. 1–6, 2022.
- [33] R. Xu, "Pathogenesis of depression and the treatment progress from traditional Chinese and Western medicine," *China Journal of Traditional Chinese Medicine and Pharmacy*, vol. 36, no. 09, pp. 5436–5440, 2021.
- [34] X. H. Li, L. N. Qin, and L. F. Xing, "Effects of electroacupuncture on behavior and expression of GLUR1 and NR2B protein in prefrontal cortex of WKY depression model rats," *Shanghai Journal of Acupuncture and Moxibustion*, vol. 40, no. 13, pp. 1–6, 2021.
- [35] X. Li, M. Q. Sun, W. Li, S. S. Li, and S. F. Xu, "Effects of electroacupuncture on behavior and expressions of p11 and 5-HTR4 in the brains of mice with chronic social defeat stress depression," *Chinese Journal of Information on Traditional Chinese Medicine*, vol. 29, no. 6, pp. 1–6, 2021.
- [36] Y. Zhang, S. S. Qu, J. P. Zhang et al., "Rapid onset of the effects of combined selective serotonin reuptake inhibitors and electroacupuncture on primary depression: a meta-analysis," *Journal of Alternative & Complementary Medicine*, vol. 22, no. 1, pp. 1–8, 2016.
- [37] X. Wang, W. Cai, Y. Wang, S. Huang, Q. Zhang, and F. Wang, "Is electroacupuncture an effective and safe treatment for poststroke depression? An updated systematic review and meta-analysis," *BioMed Research International*, vol. 2021, Article ID 8661162, 10 pages, 2021.
- [38] X. B. Li, J. Wang, A. D. Xu et al., "Clinical effects and safety of electroacupuncture for the treatment of post-stroke depression: a systematic review and meta-analysis of randomised controlled trials," *Acupuncture in Medicine*, vol. 36, no. 5, pp. 284–293, 2018.